CVR number 30605349
Industry 468100

DANSK BIOBRÆNDSEL 2005 ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  12.2% 11.0% 7.8% 8.8% 8.1%  
Credit score (0-100)  19 21 31 27 30  
Credit rating  BB BB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  570 1,021 1,124 495 443  
EBITDA  570 1,021 1,124 495 443  
EBIT  570 1,021 1,124 495 443  
Pre-tax profit (PTP)  564.5 1,013.4 1,105.7 507.0 441.4  
Net earnings  439.6 789.9 860.3 395.3 343.6  
Pre-tax profit without non-rec. items  564 1,013 1,106 507 441  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  666 1,016 1,086 622 565  
Interest-bearing liabilities  0.6 0.6 0.6 0.0 0.0  
Balance sheet total (assets)  2,398 2,843 2,161 1,013 806  
Net Debt  -1,084 -1,526 -966 -618 -487  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  570 1,021 1,124 495 443  
Gross profit growth  178.4% 78.9% 10.1% -55.9% -10.5%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,398 2,843 2,161 1,013 806  
Balance sheet change%  237.5% 18.5% -24.0% -53.1% -20.4%  
Added value  570.5 1,020.5 1,124.0 495.4 443.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  36.7% 38.9% 44.9% 32.0% 48.8%  
ROI %  108.8% 121.1% 106.9% 59.5% 74.7%  
ROE %  84.3% 93.9% 81.8% 46.3% 57.9%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  27.8% 35.7% 50.3% 61.4% 70.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -190.0% -149.6% -85.9% -124.8% -109.9%  
Gearing %  0.1% 0.1% 0.1% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  954.9% 1,133.6% 2,901.4% 305.7% 0.0%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.4 1.6 2.0 2.6 3.3  
Current Ratio  1.4 1.6 2.0 2.6 3.3  
Cash and cash equivalent  1,084.6 1,527.1 966.6 618.4 487.1  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  668.5 1,016.1 1,086.4 621.6 565.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0